ASSOCIATION OF TIRZEPATIDE WITH KIDNEY PARAMETERS IN PEOPLE WITH OBESITY AND PREDIABETES FROM SURMOUNT-1 OVER 176 WEEKS

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/d5504f9bf5473db2c0312f561b1dd2c3.pdf
ASSOCIATION OF TIRZEPATIDE WITH KIDNEY PARAMETERS IN PEOPLE WITH OBESITY AND PREDIABETES FROM SURMOUNT-1 OVER 176 WEEKS

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Yusuke
Takahashi (non-author presenter)
Hiddo J.L. Heerspink h.j.lambers.heerspink@umcg.nl University of Groningen, University Medical Center Groningen Department of Clinical Pharmacy and Pharmacology Groningen Netherlands -
Daniel H. van Raalte d.vanraalte@amsterdamumc.nl Amsterdam University Medical Center Diabetes Center, Department of Internal Medicine Amsterdam Netherlands -
Katherine Tuttle Katherine.tuttle@providence.org Providence Inland Northwest Health and University of Washington School of Medicine Providence Medical Research Center Spokane United States -
David Z.I. Cherney David.Cherney@uhn.ca Toronto General Hospital, University of Toronto Department of Medicine Toronto Canada -
Petter Bjornstad pettermb@uw.edu University of Washington School of Medicine University of Washington Medicine Diabetes Institute Seattle United States -
Carolina Piras De Oliveira carolpiras@icloud.com Eli Lilly and Company Lilly Research Laboratories Indianapolis United States -
Georgios K. Dimitriadis georgios.dimitriadis@lilly.com Eli Lilly and Company Lilly Research Laboratories Indianapolis United States -
Dachuang Cao cao_dachuang@lilly.com Eli Lilly and Company Lilly Research Laboratories Indianapolis United States -
Bruno Linetzky linetzky_bruno@lilly.com Eli Lilly and Company Lilly Research Laboratories Indianapolis United States -
Irina Jouravskaya jouravskaya_irina@lilly.com Eli Lilly and Company Lilly Research Laboratories Indianapolis United States -
Ryan Griffin ryan.griffin@lilly.com Eli Lilly and Company Lilly Research Laboratories Indianapolis United States -
Yusuke Takahashi (non-author presenter) takahashi_yusuke@lilly.com Eli Lilly Japan K.K. Japan Drug Development and Medical Affairs Kobe Japan *
-
-
-